ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Optimized renal protection with combined thymoquinone and glycine treatment: synergistic management of streptozotocin-induced nephropathy.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Complexed rifampicin with iron mitigates doxorubicin-induced nephrotoxicity.BMC pharmacology & toxicology · 2026Article
- Combining glycine with thymoquinone offers a promising strategy for diabetes treatment.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic nephropathy is still a chief reason for morbidity and mortality in persons with renal dysfunction. Thymoquinone, a primary constituent of black seed oil extracted from Nigella sativa, has anti-inflammatory, antioxidant, anticancer, and antimicrobial properties. Glycine, an amino acid and neurotransmitter, participates in diverse physiological mechanisms. This study investigated the nephroprotective role of thymoquinone and glycine against streptozotocin (STZ)-induced diabetic nephropathy. Forty-two adult male Swiss albino rats were segregated into seven groups, each comprising six. These groups consisted of control normal rats; rats administered 60-mg STZ/kg (nephropathy); nephropathy rats treated with oral doses of 20-mg/kg/day thymoquinone (T20) or 30-mg/kg/day thymoquinone (T30); nephropathy rats treated with oral doses of 50-mg/kg/day glycine (G50) or 100-mg/kg/day glycine (G100); (T + G) nephropathy rats receiving combination therapy of 30-mg/kg/day thymoquinone and 100-mg/kg/day glycine. Various biochemical factors, including glutathione (GSH), total antioxidant capacity (TAC), malondialdehyde (MDA), tumor necrosis factor-alpha (TNF-α), interleukin-10 (IL-10), total and myocardial creatine kinase (CK), kidney function parameters, blood electrolytes (Na, K, Cl, Ca, and P), and kidney histopathology, were assessed. The combined therapy of thymoquinone and glycine demonstrated enhanced efficacy in improving biochemical profiles, antioxidant levels, anti-inflammatory responses, and renal structure compared to monotherapies employing thymoquinone or glycine. The confluence of thymoquinone and glycine potentially operates through manifold pathways, encompassing the regulation of oxidative stress and modulation of inflammatory cascades. This study elucidates the potential synergistic benefits of integrating thymoquinone and glycine in diabetic nephropathy management, thereby heralding novel avenues for therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.